The phase II clinical trial (NCT03454919) of palbociclib demonstrated preliminary efficacy and acceptable safety in advanced AM patients with CDK4 gain, CCND1 gain, and/or CDKN2A loss [133]. This evidence concerns the gene CDKN2A and acute myeloblastic leukemia with maturation.